OmniAb, Inc. Annual Report (Form 10-K) Summary for the Year Ended December 31, 2025

Considering an investment in OmniAb, Inc.? Let's explore their past year, focusing on their business, financial performance, key achievements, and future prospects. OmniAb, Inc. trades on the Nasdaq Global Market under the ticker OABI (with warrants as OABIW).

Business Overview OmniAb discovers and develops therapeutic antibodies. The company operates a specialized platform that generates diverse, high-quality antibodies. Partners then take these antibody candidates forward into clinical development. OmniAb's core business involves licensing its advanced antibody discovery platforms – such as specialized animal models and AI-powered screening tools – to pharmaceutical and biotech companies. Its revenue comes from upfront license fees, research funding, milestone payments when partner programs advance, and potential future royalties on approved products. OmniAb's strategy focuses on expanding its partner network, continuously improving its technology platform through R&D, and supporting partner programs to maximize their chances of clinical and commercial success. OmniAb filed its annual report for the fiscal year ending December 31, 2025. As a "smaller reporting company" and an "emerging growth company," OmniAb benefits from reduced public reporting requirements. As of June 30, 2025, the market value of OmniAb's publicly traded stock (its "free float") was approximately $144.9 million. The company had about 144.8 million shares of common stock outstanding as of February 25, 2026.

Financial Performance OmniAb reported total revenue of $28.5 million for the fiscal year ending December 31, 2025, an increase from $21.2 million in the previous year. New collaboration agreements and milestone achievements primarily drove this growth. Despite this revenue growth, the company reported a net loss of $45.1 million, up from a $38.7 million net loss in 2024. This larger loss reflects significant investments in research and development (R&D), totaling $55.3 million for the year, as OmniAb continues to enhance its platform and support partner programs.

Risk Factors Investing in OmniAb involves several inherent risks. The company's success heavily depends on the clinical and commercial success of its partners' drug candidates. These candidates face lengthy and uncertain development processes, including regulatory approvals. Other critical risks include intense competition in antibody discovery, the need for substantial future funding for R&D and operations, and protecting its intellectual property. As an emerging growth company, OmniAb may also have less robust internal controls and financial reporting infrastructure than larger, more mature companies, potentially impacting financial reporting and operational efficiency. The company also faces risks related to attracting and retaining key personnel, changes in the regulatory landscape, and potential cybersecurity threats.

Management's Discussion and Analysis (MD&A) Highlights Management highlighted that new collaboration agreements and specific development milestones achieved by its partners primarily drove the revenue increase in 2025. The larger net loss directly resulted from strategic investments in research and development. These investments aim to expand the company's technology platform and support partner program progression. Management considers these investments crucial for long-term growth and competitive differentiation. Operationally, 2025 saw significant progress: OmniAb secured four new strategic collaboration agreements and advanced two partner-driven antibody candidates into Phase 1 clinical trials. The company also emphasized its ongoing efforts to enhance platform capabilities by introducing new screening methodologies designed to accelerate antibody discovery timelines.

Financial Health As of December 31, 2025, OmniAb held $62.8 million in cash and cash equivalents. Management believes this amount is sufficient to fund operations for at least the next 12-18 months. The company reported no significant long-term debt as of December 31, 2025. It relies primarily on equity financing and operational cash flow for its capital needs. This strong cash position and minimal debt provide financial flexibility to support ongoing R&D and operational expenses.

Future Outlook Looking ahead, OmniAb plans to expand its global partner network, invest in cutting-edge R&D to further differentiate its platform, and support the progression of its partnered programs through clinical development. The company aims to leverage its technology to address a broader range of therapeutic areas, increasing its potential for future royalty streams. OmniAb outlined its strategic priorities. Investors should monitor the progress of partner programs and the company's ability to secure additional funding as key indicators of future performance.

Competitive Position The antibody discovery market is highly competitive, marked by rapid technological advancements. It includes both established pharmaceutical companies with extensive in-house capabilities and specialized biotechnology firms offering similar platform technologies. OmniAb differentiates itself through its specialized animal models and AI-powered screening technologies. These tools generate diverse and high-quality antibody candidates. Key competitive factors include the breadth and quality of antibody libraries, discovery speed, intellectual property protection, and the ability to secure and maintain strategic partnerships. The company continuously invests in R&D to maintain its technological edge and competitive differentiation, aiming for a leading position in the outsourced antibody discovery services market.